CD14 and autoimmune disease: Our results, the first focused on endogenous exposure to GC, were similar to those of Liu et al., who showed increased intermediate CD14+CD16+ monocytes after treatment in patients with autoimmune disease [18]; moreover, GC treatment directly affected CD16 expression.